Emh Regional Medical Center
Emh Regional Medical Center was paid $41.46M by Medicaid between Jan 2018 and Dec 2024, across 347 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
ELYRIA, OH 44035
Next to other General Acute Care Hospital providers in Ohio
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 151,916 | $5.29M | |
| 2019 | 111,871 | $4.24M | |
| 2020 | 75,654 | $4.38M | |
| 2021 | 83,693 | $4.32M | |
| 2022 | 84,627 | $4.33M | |
| 2023 | 282,972 | $11.40M | |
| 2024incomplete | 209,233 | $7.51M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 71,111 | 67,094 | $8.27M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 37,894 | 34,497 | $5.05M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 13,859 | 11,606 | $4.32M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.4% | 27,110 | 23,788 | $3.47M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.1% | 15,740 | 14,343 | $2.13M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 4.5% | 18,107 | 15,605 | $1.87M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 6,544 | 5,504 | $1.63M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.3% | 19,056 | 6,865 | $1.38M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.1% | 9,291 | 8,512 | $1.27M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 5,522 | 4,522 | $1.27M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 4,804 | 3,227 | $708K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 2,243 | 1,879 | $580K |
335 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 1,812 | $470K |
| 20610 | 1.1% | 3,376 | $459K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,664 | $398K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,309 | $393K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,603 | $390K |
| 80053 | Comprehensive metabolic panel | <1% | 45,659 | $360K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,628 | $354K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,176 | $353K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,742 | $336K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,985 | $249K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 602 | $222K |
| 11043 | <1% | 842 | $195K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,136 | $190K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 295 | $188K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,619 | $174K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,329 | $162K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 734 | $162K |
| G0378 | Hospital observation service, per hour | <1% | 2,928 | $160K |
| 11045 | <1% | 661 | $152K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,990 | $118K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,438 | $112K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,050 | $105K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 9,353 | $100K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,679 | $96K |
| 73610 | <1% | 3,684 | $89K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 31,139 | $89K |
| 76770 | <1% | 524 | $83K | |
| 97161 | <1% | 2,001 | $79K | |
| 93017 | <1% | 932 | $77K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,010 | $73K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 799 | $70K |
| 73110 | <1% | 2,828 | $69K | |
| 73630 | <1% | 3,705 | $68K | |
| 95886 | <1% | 244 | $67K | |
| 97113 | <1% | 880 | $66K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 804 | $64K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,669 | $60K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,029 | $60K |
| 20526 | <1% | 301 | $57K | |
| 73140 | <1% | 1,998 | $56K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,262 | $53K |
| 20611 | <1% | 228 | $53K | |
| 87631 | <1% | 572 | $52K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 501 | $52K |
| 84484 | <1% | 21,651 | $52K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 61,096 | $50K |
| 73130 | <1% | 2,638 | $50K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,667 | $49K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 187 | $47K |
| 70491 | <1% | 162 | $47K | |
| 73564 | <1% | 2,200 | $47K | |
| 71250 | <1% | 597 | $46K | |
| 12001 | <1% | 290 | $45K | |
| 93971 | <1% | 719 | $45K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 280 | $42K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,805 | $41K |
| 73030 | <1% | 2,076 | $40K | |
| 97165 | <1% | 834 | $38K | |
| 83605 | <1% | 13,252 | $37K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,722 | $35K |
| 72110 | <1% | 763 | $35K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,140 | $33K |
| 86850 | <1% | 1,718 | $33K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,169 | $32K |
| 82607 | <1% | 1,246 | $31K | |
| 80320 | <1% | 1,748 | $31K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 247 | $31K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,044 | $29K |
| 72131 | <1% | 543 | $29K | |
| 25600 | <1% | 104 | $29K | |
| 76536 | <1% | 272 | $29K | |
| 73560 | <1% | 1,096 | $28K | |
| 76642 | <1% | 239 | $27K | |
| 70486 | <1% | 596 | $27K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,273 | $26K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,715 | $26K |
| 93970 | <1% | 225 | $25K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 28,266 | $25K |
| 93458 | <1% | 27 | $24K | |
| 76830 | Ultrasound, transvaginal | <1% | 997 | $24K |
| 82805 | <1% | 822 | $24K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 1,579 | $24K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 285 | $24K |
| 93880 | <1% | 297 | $24K | |
| 73562 | <1% | 838 | $23K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,952 | $23K |
| 83880 | <1% | 4,666 | $22K | |
| 73502 | <1% | 1,082 | $22K | |
| 70496 | <1% | 100 | $22K | |
| 80061 | Lipid panel | <1% | 2,028 | $22K |
| 86900 | <1% | 1,881 | $21K | |
| 93975 | <1% | 145 | $21K | |
| 73221 | <1% | 119 | $21K | |
| 97162 | <1% | 574 | $21K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 74 | $19K |
| 74018 | <1% | 468 | $19K | |
| 73080 | <1% | 806 | $19K | |
| 20550 | <1% | 125 | $18K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 943 | $18K |
| 85027 | <1% | 4,396 | $18K | |
| 72100 | <1% | 672 | $18K | |
| 87040 | <1% | 2,281 | $17K | |
| 96367 | <1% | 453 | $17K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,261 | $14K |
| 93296 | <1% | 783 | $13K | |
| 64721 | <1% | 14 | $13K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 20,469 | $13K |
| 27786 | <1% | 42 | $13K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 32 | $12K |
| 29075 | <1% | 89 | $12K | |
| 87510 | <1% | 724 | $11K | |
| 74174 | <1% | 271 | $11K | |
| 90715 | <1% | 754 | $11K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 376 | $11K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 9,636 | $11K |
| 73590 | <1% | 643 | $10K | |
| 82947 | <1% | 6,862 | $10K | |
| 81001 | <1% | 20,841 | $10K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,241 | $10K |
| 81003 | <1% | 17,982 | $9K | |
| 72050 | <1% | 203 | $9K | |
| 95910 | <1% | 87 | $9K | |
| 87660 | <1% | 713 | $9K | |
| 87480 | <1% | 724 | $9K | |
| 74019 | <1% | 141 | $8K | |
| 83735 | <1% | 8,723 | $8K | |
| 85610 | <1% | 11,132 | $8K | |
| 85379 | <1% | 2,476 | $8K | |
| 86780 | <1% | 323 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,674 | $8K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,009 | $7K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,291 | $7K |
| 73700 | <1% | 61 | $7K | |
| 84702 | <1% | 4,551 | $7K | |
| 96376 | <1% | 2,822 | $7K | |
| 87205 | <1% | 1,486 | $7K | |
| 73090 | <1% | 410 | $7K | |
| 86901 | <1% | 1,890 | $7K | |
| 87800 | <1% | 564 | $6K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 259 | $6K |
| 99152 | <1% | 475 | $6K | |
| 82570 | <1% | 518 | $6K | |
| 95816 | <1% | 45 | $5K | |
| 11046 | <1% | 31 | $5K | |
| 70498 | <1% | 102 | $5K | |
| 72040 | <1% | 167 | $5K | |
| 83690 | <1% | 13,413 | $5K | |
| J3490 | Unclassified drugs | <1% | 3,024 | $5K |
| 12002 | <1% | 30 | $4K | |
| 94726 | <1% | 82 | $4K | |
| 93298 | <1% | 254 | $4K | |
| 72128 | <1% | 174 | $4K | |
| 97116 | <1% | 258 | $4K | |
| 80076 | <1% | 2,202 | $4K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 312 | $3K |
| 82077 | <1% | 2,731 | $3K | |
| 86140 | <1% | 1,363 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,571 | $3K |
| 82043 | <1% | 491 | $3K | |
| 84156 | <1% | 491 | $3K | |
| 97016 | <1% | 84 | $3K | |
| 10060 | <1% | 17 | $3K | |
| 95861 | <1% | 15 | $3K | |
| 20600 | <1% | 19 | $3K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 110 | $3K |
| 84439 | <1% | 224 | $3K | |
| 87081 | <1% | 1,318 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 335 | $2K |
| 84703 | <1% | 4,826 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 860 | $2K |
| 12011 | <1% | 15 | $2K | |
| 85730 | <1% | 4,284 | $2K | |
| 73552 | <1% | 123 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,083 | $2K |
| 94729 | <1% | 106 | $2K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 137 | $2K |
| 80143 | <1% | 2,127 | $2K | |
| 81025 | <1% | 5,945 | $2K | |
| 82550 | <1% | 2,125 | $2K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 12 | $2K |
| 87070 | <1% | 1,112 | $2K | |
| 87077 | <1% | 667 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,971 | $2K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 25 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 121 | $2K |
| 76870 | <1% | 75 | $2K | |
| 87634 | <1% | 881 | $2K | |
| 72170 | <1% | 392 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 163 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,423 | $1K |
| 87186 | <1% | 1,076 | $1K | |
| 82150 | <1% | 2,010 | $1K | |
| 87340 | <1% | 102 | $1K | |
| 88142 | <1% | 97 | $1K | |
| 86803 | <1% | 90 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,465 | $1K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 400 | $1K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 201 | $1K |
| 82330 | <1% | 613 | $1K | |
| 76937 | <1% | 33 | $1K | |
| 94150 | <1% | 48 | $1K | |
| 87075 | <1% | 1,718 | $1K | |
| A9270 | Non-covered item or service | <1% | 8,968 | $1K |
| 73660 | <1% | 28 | $953.00 | |
| 73000 | <1% | 59 | $910.34 | |
| 80179 | <1% | 2,084 | $882.76 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 152 | $877.28 |
| 85007 | <1% | 119 | $823.47 | |
| 93922 | <1% | 12 | $780.88 | |
| 94200 | <1% | 34 | $775.73 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,055 | $742.72 |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | <1% | 40 | $734.47 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 915 | $695.01 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,023 | $626.85 |
| 84132 | <1% | 1,026 | $607.41 | |
| 83970 | <1% | 18 | $578.82 | |
| 86762 | <1% | 30 | $575.86 | |
| 82746 | <1% | 41 | $554.67 | |
| 88300 | <1% | 12 | $531.91 | |
| 73060 | <1% | 87 | $522.18 | |
| 83655 | <1% | 14 | $513.63 | |
| 77066 | Tomosynthesis, mammo | <1% | 47 | $512.86 |
| 82728 | <1% | 38 | $480.50 | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 252 | $477.97 |
| 84100 | <1% | 612 | $471.30 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,259 | $466.89 |
| 85018 | <1% | 620 | $443.69 | |
| 86141 | <1% | 996 | $433.08 | |
| 86787 | <1% | 41 | $430.55 | |
| 72120 | <1% | 113 | $429.43 | |
| 82435 | <1% | 549 | $424.51 | |
| 29125 | <1% | 91 | $404.23 | |
| 84153 | <1% | 18 | $397.60 | |
| 77062 | <1% | 13 | $391.49 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,365 | $379.36 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,696 | $373.55 |
| 85652 | <1% | 546 | $369.29 | |
| 93297 | <1% | 17 | $338.05 | |
| 93280 | <1% | 29 | $331.54 | |
| 82950 | <1% | 38 | $328.21 | |
| 83721 | <1% | 28 | $326.41 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 935 | $326.22 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,312 | $320.86 |
| 82248 | <1% | 1,077 | $299.08 | |
| 80069 | <1% | 21 | $294.87 | |
| 74022 | <1% | 26 | $292.77 | |
| 83540 | <1% | 45 | $287.01 | |
| 87807 | <1% | 1,111 | $276.56 | |
| 88112 | <1% | 12 | $271.02 | |
| 76801 | <1% | 103 | $260.72 | |
| J7328 | Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | <1% | 62 | $254.05 |
| 83550 | <1% | 37 | $247.44 | |
| 90686 | <1% | 19 | $240.34 | |
| 84295 | <1% | 551 | $237.38 | |
| 36600 | <1% | 245 | $230.05 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,962 | $228.79 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 436 | $209.76 |
| J7999 | Compounded drug, not otherwise classified | <1% | 285 | $204.39 |
| 93290 | <1% | 37 | $203.75 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,433 | $191.66 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,564 | $180.36 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,494 | $153.65 |
| 82010 | <1% | 243 | $149.93 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,351 | $134.58 |
| G0404 | Electrocardiogram, routine ecg with 12 leads; tracing only, without interpretation and report, performed as a screening for the initial preventive physical examination | <1% | 147 | $130.22 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,047 | $113.41 |
| 80329 | <1% | 180 | $109.83 | |
| 0753T | <1% | 72 | $109.47 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 247 | $105.85 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,551 | $105.58 |
| 29515 | <1% | 13 | $100.43 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 335 | $98.19 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 1,148 | $89.07 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 403 | $85.01 |
| J7070 | Infusion, d5w, 1000 cc | <1% | 124 | $80.67 |
| 82948 | <1% | 201 | $62.41 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 761 | $58.71 |
| 84550 | <1% | 34 | $57.84 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 920 | $57.49 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 406 | $55.65 |
| 94762 | <1% | 26 | $53.94 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,138 | $53.77 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 503 | $53.70 |
| 73100 | <1% | 154 | $52.76 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,346 | $52.00 |
| 94761 | <1% | 1,278 | $51.99 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,013 | $51.83 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 174 | $50.71 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 452 | $49.96 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,065 | $49.03 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 200 | $41.74 |
| 72114 | <1% | 38 | $40.31 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,144 | $35.50 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 509 | $33.73 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,032 | $33.11 |
| C1769 | Guide wire | <1% | 232 | $29.16 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 906 | $25.97 |
| 86308 | <1% | 76 | $25.74 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 485 | $22.89 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 69 | $21.74 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 181 | $19.00 |
| 81002 | <1% | 20 | $12.39 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 29 | $11.58 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 29 | $11.18 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 500 | $10.95 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 123 | $10.78 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 490 | $8.21 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 143 | $6.79 |
| 76377 | <1% | 833 | $5.27 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 143 | $4.96 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 50 | $4.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 37 | $3.98 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 96 | $2.50 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 33 | $2.34 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 183 | $0.48 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 316 | $0.32 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 158 | $0.00 |
| 82803 | 0% | 43 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 271 | $0.00 |
| 94760 | 0% | 292 | $0.00 | |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 56 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 12 | $0.00 |
| G0269 | Placement of occlusive device into either a venous or arterial access site, post surgical or interventional procedure (e.g., angioseal plug, vascular plug) | 0% | 23 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 611 | $0.00 |
| 87185 | 0% | 14 | $0.00 | |
| 01810 | 0% | 13 | $0.00 | |
| 94664 | 0% | 42 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 41 | $0.00 |
| 00840 | 0% | 179 | $0.00 | |
| 00811 | 0% | 37 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 64 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 18 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 54 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 12 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.